The Impact of Cannabidiol (CBD) on Sleep Quality: A Review of Mechanisms and Clinical Evidence
DOI:
https://doi.org/10.12775/QS.2025.48.67087Keywords
Cannabidiol (CBD), Insomnia, Sleep Quality, REM sleep, slow-wave sleep, clinical trials, endocannabinoid systemAbstract
Cannabidiol (CBD), a non-psychoactive component of Cannabis sativa, has garnered significant interest as a potential therapeutic agent for sleep disturbances. This review synthesizes preclinical and clinical evidence on the effects of CBD on sleep parameters, including sleep architecture, quality, and disorders such as insomnia and REM sleep behavior disorder (RBD). Preclinical studies reveal that CBD modulates sleep architecture in a dose- and region-dependent manner, influencing both slow-wave and REM sleep. These effects are mediated through complex interactions with the endocannabinoid, adenosinergic, serotonergic, dopaminergic, and GABAergic systems. Clinical trials suggest that low to moderate doses of CBD may modestly improve subjective sleep quality, particularly in individuals with co-occurring anxiety or chronic pain, although its efficacy is generally comparable to melatonin. High-dose CBD may enhance restorative sleep stages, yet the benefits are limited and inconsistently sustained. CBD demonstrates a favorable safety profile, though methodological limitations—such as small sample sizes, short follow-up durations, and product variability—impede definitive conclusions. Further research with standardized formulations, objective sleep measurements, and larger populations with diagnosed sleep disorders is needed to fully assess the therapeutic potential and clinical application of CBD for sleep-related conditions.
References
1. Jain DrJ, Kapoor DrR, Adlakha DrM, Kumar DrA, Tiwari DrA. Importance of Proper Sleep in Healthy Life. IJRASET. 2022 Oct 31;10(10):1035–40.
2. Medic G, Wille M, Hemels M. Short- and long-term health consequences of sleep disruption. NSS. 2017 May;Volume 9:151–61.
3. Perry GS, Patil SP, Presley-Cantrell LR. Raising Awareness of Sleep as a Healthy Behavior. Prev Chronic Dis. 2013 Aug 8;10:130081.
4. Ohlmann KK, O’Sullivan MI, Berryman P, Lukes E. The Costs of Short Sleep. AAOHN Journal. 2009 Sep;57(9):381–7.
5. Campos AC, Fogaça MV, Sonego AB, Guimarães FS. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacological Research. 2016 Oct;112:119–27.
6. Sideris A, Doan LV. An Overview of Cannabidiol. Anesthesia & Analgesia. 2024 Jan;138(1):54–68.
7. Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Phil Trans R Soc B. 2012 Dec 5;367(1607):3364–78.
8. Efficacy and Safety of Cannabidiol Oil on Chronic Insomnia: The First Randomized, Double-Blind, Placebo-Controlled, Crossover, Pilot Study in Thailand. J Med Assoc Thai. 2024 Mar 19;107(3):160–70.
9. Narayan AJ, Downey LA, Rose S, Di Natale L, Hayley AC. Cannabidiol for moderate–severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. Journal of Clinical Sleep Medicine. 2024 May;20(5):753–63.
10. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of Cannabidiol in the Management of Insomnia: A Systematic Review. Cannabis and Cannabinoid Research. 2022 Sep 23;can.2022.0122.
11. Suraev A, Grunstein RR, Marshall NS, D’Rozario AL, Gordon CJ, Bartlett DJ, et al. Cannabidiol (CBD) and Δ9 -tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial. BMJ Open. 2020 May;10(5):e034421.
12. Murillo-Rodriguez E, Poot-Ake A, Arias-Carrion O, Pacheco-Pantoja E, De La Fuente-Ortegon A, Arankowsky-Sandoval G. The Emerging Role of the Endocannabinoid System in the Sleep-Wake Cycle Modulation. CNSAMC. 2011 Sep 1;11(3):189–96.
13. Kaul M, Zee PC, Sahni AS. Effects of Cannabinoids on Sleep and their Therapeutic Potential for Sleep Disorders. Neurotherapeutics. 2021 Jan;18(1):217–27.
14. Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Curr Psychiatry Rep. 2017 Apr;19(4):23.
15. Miranda A, Peek E, Ancoli-Israel S, Young JW, Perry W, Minassian A. The Role of Cannabis and The Endocannabinoid System in Sleep Regulation and Cognition: A Review of Human and Animal Studies. Behavioral Sleep Medicine. 2024 Mar 3;22(2):217–33.
16. Kesner AJ, Lovinger DM. Cannabinoids, Endocannabinoids and Sleep. Front Mol Neurosci. 2020 Jul 22;13:125.
17. Henson J, Vitetta L, Quezada M, Hall S. Enhancing Endocannabinoid Control of Stress with Cannabidiol. JCM. 2021 Dec 14;10(24):5852.
18. Skelley JW, Deas CM, Curren Z, Ennis J. Use of cannabidiol in anxiety and anxiety-related disorders. Journal of the American Pharmacists Association. 2020 Jan;60(1):253–61.
19. Lookfong NA, Raup-Konsavage WM, Silberman Y. Potential Utility of Cannabidiol in Stress-Related Disorders. Cannabis and Cannabinoid Research. 2022 Nov 21;can.2022.0130.
20. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015 Oct;12(4):825–36.
21. Bakas T, Van Nieuwenhuijzen PS, Devenish SO, McGregor IS, Arnold JC, Chebib M. The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors. Pharmacological Research. 2017 May;119:358–70.
22. Han K, Wang JY, Wang PY, Peng YCH. Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis. Psychiatry Research. 2024 Sep;339:116049.
23. Guldager MB, Biojone C, Da Silva NR, Godoy LD, Joca S. New insights into the involvement of serotonin and BDNF-TrkB signalling in cannabidiol’s antidepressant effect. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2024 Jul;133:111029.
24. Ruffolo G, Gaeta A, Cannata B, Pinzaglia C, Aronica E, Morano A, et al. GABAergic Neurotransmission in Human Tissues Is Modulated by Cannabidiol. Life. 2022 Dec 6;12(12):2042.
25. Campos AC, Fogaça MV, Scarante FF, Joca SRL, Sales AJ, Gomes FV, et al. Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders. Front Pharmacol. 2017 May 23;8:269.
26. Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and Anti-Inflammatory Properties of Cannabidiol. Antioxidants. 2019 Dec 25;9(1):21.
27. Mlost J, Bryk M, Starowicz K. Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action. IJMS. 2020 Nov 23;21(22):8870.
28. Arout CA, Haney M, Herrmann ES, Bedi G, Cooper ZD. A placebo‐controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans. Brit J Clinical Pharma. 2022 Jan;88(1):347–55.
29. Jean‐Gilles L, Braitch M, Latif ML, Aram J, Fahey AJ, Edwards LJ, et al. Effects of pro‐inflammatory cytokines on cannabinoid CB1 and CB2 receptors in immune cells. Acta Physiologica. 2015 May;214(1):63–74.
30. Sales AJ, Crestani CC, Guimarães FS, Joca SRL. Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2018 Aug;86:255–61.
31. D’Angelo M, Steardo L. Cannabinoids and Sleep: Exploring Biological Mechanisms and Therapeutic Potentials. IJMS. 2024 Mar 22;25(7):3603.
32. Chagas MHN, Crippa JAS, Zuardi AW, Hallak JEC, Machado-de-Sousa JP, Hirotsu C, et al. Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. J Psychopharmacol. 2013 Mar;27(3):312–6.
33. Samanta A, Aleman-Zapata A, Agarwal K, Özsezer P, Alonso A, Van Der Meij J, et al. CBD lengthens sleep but shortens ripples and leads to intact simple but worse cumulative memory. iScience. 2023 Nov;26(11):108327.
34. Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Mechoulam R, Drucker-Colín R. Cannabidiol, a constituent of Cannabis sativa , modulates sleep in rats. FEBS Letters. 2006 Aug 7;580(18):4337–45.
35. Hsiao YT, Yi PL, Li CL, Chang FC. Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats. Neuropharmacology. 2012 Jan;62(1):373–84.
36. Narayan AJ, Downey LA, Rose S, Di Natale L, Hayley AC. Cannabidiol for moderate–severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. Journal of Clinical Sleep Medicine. 2024 May;20(5):753–63.
37. Saleska JL, Bryant C, Kolobaric A, D’Adamo CR, Colwell CS, Loewy D, et al. The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. Journal of the American Nutrition Association. 2024 Jan 2;43(1):1–11.
38. Wang M, Faust M, Abbott S, Patel V, Chang E, Clark JI, et al. Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study. Journal of Clinical Sleep Medicine. 2025 Jan;21(1):69–80.
39. De Almeida CMO, Brito MMC, Bosaipo NB, Pimentel AV, Tumas V, Zuardi AW, et al. Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder. Movement Disorders. 2021 Jul;36(7):1711–5.
40. Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in Anxiety and Sleep: A Large Case Series. TPJ. 2019 Mar;23(1):18–041.
41. Suraev AS, Marshall NS, Vandrey R, McCartney D, Benson MJ, McGregor IS, et al. Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. Sleep Medicine Reviews. 2020 Oct;53:101339.
42. Saleska JL, Bryant C, Kolobaric A, D’Adamo CR, Colwell CS, Loewy D, et al. The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. Journal of the American Nutrition Association. 2024 Jan 2;43(1):1–11.
43. Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in Anxiety and Sleep: A Large Case Series. TPJ. 2019 Mar;23(1):18–041.
44. AminiLari M, Wang L, Neumark S, Adli T, Couban RJ, Giangregorio A, et al. Medical cannabis and cannabinoids for impaired sleep: a systematic review and meta-analysis of randomized clinical trials. Sleep. 2022 Feb 14;45(2):zsab234.
45. McParland AL, Bhatia A, Matelski J, Tian C, Diep C, Clarke H, et al. Evaluating the impact of cannabinoids on sleep health and pain in patients with chronic neuropathic pain: a systematic review and meta-analysis of randomized controlled trials. Reg Anesth Pain Med. 2023 Apr;48(4):180–90.
46. Suraev AS, Marshall NS, Vandrey R, McCartney D, Benson MJ, McGregor IS, et al. Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. Sleep Medicine Reviews. 2020 Oct;53:101339.
47. Johnson K, Weldon AJ, Burmeister MA. Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen. Front Psychiatry. 2024 Apr 23;15:1386263.
48. Gates PJ, Albertella L, Copeland J. The effects of cannabinoid administration on sleep: a systematic review of human studies. Sleep Medicine Reviews. 2014 Dec;18(6):477–87.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Aleksandra Miszkurka, Marcin Komorowski, Aleksandra Zagajewska, Joanna Piecek, Michał Janiszewski, Dominika Ziętara, Kacper Kmieć, Marta Omiecińska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 3
Number of citations: 0
